BIT

5.00%

1.9¢ biotron limited

Ann: Letter to Shareholders, page-96

First 96 Last

Share
Profile

Follow
Scooterdog

6,067 Posts.

251

16/07/24

12:49

Post #: 74773548
Share

Originally posted by NZ Trader: ↑

Always in the vacuum of News/ Updates there are questions surrounding "what are management up to , what are they achieving"?

SH need to focus on the Game and not the players ... just because there is no market action doesn't mean that Management are inactive..
Had a little more time to reflect on the last presentation , The CEO obviously has ignored previous correspondence from certain SH? in this game you have to "Craft" your questions so a CEO has the ability to answer...
The recent message is " We have signed hundreds of NDA's" "we can not disclose who we are in Discussions with"
Plus the big one I believe the market missed " We have Met our Primary Endpoints"

BIT225-011 Phase 2 HIV Exploratory Efficacy Trial Meets Primary Objectives

 Preliminary analyses indicate that the primary objectives of the trial have been met.
 The results extend the previously reported effects of BIT225 to an HIV-infected population that has
not achieved full immune reconstitution despite long-term suppressive antiretroviral treatment.

The Directors of Biotron Limited (the Company) are pleased to advise that preliminary analyses of data from
the BIT225-011 Phase 2 clinical trial of the Company’s lead antiviral drug BIT225 indicate that the primary
objectives of the trial have been met.

This longitudinal, open-label Phase 2 trial was designed to characterise the effect of BIT225 (200 mg, once
daily) added to ongoing, suppressive standard of care antiretroviral therapy (cART) for twelve weeks in twenty
HIV-1 infected, treatment-experienced participants who had achieved only partial immune reconstitution. Trial
details are set out in the attached Addendum.
The primary objectives of the trial were to evaluate the safety and tolerability of BIT225 in this patient
population, as well as to determine the impact of the addition of BIT225 to cART on immune activation,
inflammation and viral markers.

Understand many are jaded with the Company and management but do keep in mind "All those that hold are Invested n the Same Company"
Varying Views and Opinions are always welcomed on the Forums but just openly abusing and slagging other Posters does nothing to assist with welcoming potential new investors.. NZT

Expand

Lord of the fly’s is slagging BIT daily to suit it’s own agenda, very different story to what goes on with the stock it owns.

BIT Price at posting: 3.5¢ Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BUX

Buxton projects new graphite province discovery at WA Narryer play

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 62 more messages in this thread...

First 96 Last

Add BIT (ASX) to my watchlist

(20min delay)
Last 1.9¢		Change -0.001(5.00%)		Mkt cap ! $17.14M

Open	High	Low	Value	Volume
1.9¢	1.9¢	1.9¢	$5.671K	298.4K

Buyers (Bids)

No.	Vol.	Price($)
3	512798	1.9¢

Sellers (Offers)

Price($)	Vol.	No.
2.0¢	1050263	5

View Market Depth

No.	Vol.	Price($)
3	512798	0.019
10	1774771	0.018
8	927388	0.017
12	3258350	0.016
7	865000	0.015

Price($)	Vol.	No.
0.020	1000263	4
0.021	555000	2
0.022	997769	4
0.023	1100772	2
0.024	153949	2

Last trade - 15.59pm 04/10/2024 (20 minute delay)

BIT (ASX) Chart

Ann: Letter to Shareholders, page-96

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Letter to Shareholders, page-96

Top Stories

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News